MARKET

TEVA

TEVA

Teva Pharm Ind
NYSE

Real-time Quotes | Nasdaq Last Sale

9.01
+0.16
+1.81%
After Hours: 9.02 +0.01 +0.11% 19:51 09/30 EDT
OPEN
8.94
PREV CLOSE
8.85
HIGH
9.20
LOW
8.89
VOLUME
9.05M
TURNOVER
--
52 WEEK HIGH
13.76
52 WEEK LOW
6.25
MARKET CAP
9.87B
P/E (TTM)
3465.38
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Watch live: Pharma executives testify at House hearing on drug pricing
The U.S. House of Representatives Oversight and Reform Committee is holding a hearing with current and former executives of three major drug companies on the high cost of prescription drugs in the U.S.
CNBC.com · 16h ago
Surge in Drug Prices Tied to Revenue, Million-Dollar Bonuses
Bloomberg · 17h ago
Collegium settles Xtampza patent dispute with Teva
Collegium Pharmaceutical (COLL) has settled its patent infringement litigation with Teva Pharmaceutical Industries (TEVA) related to the latter's U.S. marketing application seeking approval of a generic version of abuse-deterrent opioid
Seekingalpha · 18h ago
BofA dives into Quality Value as a rotation looks to get under way
Value investing started to see some "signs of life" in September, BofA says - another coincident indicator with an economy recovering from a brutal recession - but it's a rotation
Seekingalpha · 1d ago
Is JNJ Stock A Buy As Pharma Giant Starts Final-Phase Coronavirus Vaccine Trials?
Investor's Business Daily · 5d ago
Why Investors Should Take a Serious, Bullish Look on Sorrento
Renewed interest in emerging biotechnology companies lifted Sorento Therapeutics (NASDAQ:SRNE) recently. Excessive bearish volumes against the stock could squeeze them out further. If Sorrento continues to post positive news in its drug and testing developments on the novel coronavirus, then SRNE stock
InvestorPlace · 5d ago
FDA issues final rule for importation of drugs from abroad
Following through on President Trump's Executive Order in July aimed at cutting U.S. drug costs via importation, the FDA issues its final rule on allowing agency-authorized programs to import medicines,
Seekingalpha · 5d ago
U.S. appeals court rejects novel opioid settlement framework
A federal appeals court on Thursday overturned a judge's approval of a novel plan by lawyers representing cities and counties suing drug companies over the U.S. opioid epidemic that would bring every community nationally into their settlement talks. The 6th U.S. Circuit Court of Appeals by a 2-1
Reuters · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TEVA. Analyze the recent business situations of Teva Pharm Ind through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 23 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TEVA stock price target is 12.19 with a high estimate of 17.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 510
Institutional Holdings: 653.76M
% Owned: 59.66%
Shares Outstanding: 1.10B
TypeInstitutionsShares
Increased
147
66.40M
New
44
7.03M
Decreased
126
58.00M
Sold Out
97
38.62M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.51%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Chairman/Independent Director
Sol Barer
President/Chief Executive Officer/Director
Kaare Schultz
Chief Financial Officer/Executive Vice President/Director
Eli Kalif
Chief Financial Officer/Executive Vice President
Eliyahu Kalif
Chief Human Resource Officer/Executive Vice President
Mark Sabag
Executive Vice President
Richard Daniell
Executive Vice President
Sven Dethlefs
Executive Vice President
Eric Drape
Executive Vice President
Hafrun Fridriksdottir
Executive Vice President
Gianfranco Nazzi
Executive Vice President
Brendan O'Grady
Executive Vice President
David Stark
Independent Director
Rosemary Crane
Independent Director
Amir Elstein
Independent Director
Jean-Michel Halfon
Independent Director
Abbas Hussain
Independent Director
Gerald Lieberman
Independent Director
Roberto Mignone
Independent Director
Perry Nisen
Independent Director
Nechemia Peres
Independent Director
Ronit Satchi-Fainaro
Independent Director
Janet Vergis
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.072
11/27/2017
08/04/2017
Dividend USD 0.072
08/25/2017
05/16/2017
Dividend USD 0.289
06/01/2017
03/16/2017
Dividend USD 0.289
02/28/2017
11/17/2016
Dividend USD 0.289
12/01/2016
08/08/2016
Dividend USD 0.289
08/18/2016
05/11/2016
Dividend USD 0.289
05/20/2016
02/16/2016
Dividend USD 0.289
02/25/2016
11/02/2015
Dividend USD 0.289
11/13/2015
07/31/2015
Dividend USD 0.289
08/18/2015
05/05/2015
Dividend USD 0.289
05/15/2015
02/20/2015
Dividend USD 0.294
02/17/2015
11/18/2014
Dividend USD 0.27
11/13/2014
08/25/2014
Dividend USD 0.291
08/19/2014
05/20/2014
Dividend USD 0.298
05/16/2014
03/05/2014
Dividend USD 0.293
02/20/2014
11/21/2013
Dividend USD 0.278
11/18/2013
08/21/2013
Dividend USD 0.274
08/16/2013
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Teva Pharmaceutical Industries Ltd (ADR) stock information, including NYSE:TEVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TEVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TEVA stock methods without spending real money on the virtual paper trading platform.